ACIP Recommends Pneumococcal Conjugate Vaccine for HIV-Infected Adults

PCV13 should be given at least 8 weeks before the first PPSV23 dose or, in patients with previous PPSV23 vaccination, at least 1 year after PPSV23 administration.

Since 1989, immunization with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been recommended for persons with immunocompromising conditions, including HIV infection. Now, the Advisory Committee on Immunization Practices (ACIP) recommends that HIV-infected adults also receive the 13-valent pneumococcal conjugate vaccine (PCV13), which shares 12 serotypes with PPSV23. PCV13 should be given ≥8 weeks before the first dose of PPSV23 or, in individuals with previous PPSV23 vaccination, ≥1 year after PPSV23 administration.

In making these recommendations, the ACIP notes that the incidence of invasive disease caused by Streptococcus pneumoniae remains high in HIV-infected individuals compared with the general population, and that ma…

Authors

Kevin L. Ard, MD, MPH

Paul Sax, MD

Disclosures

Consultant/Advisory BoardGilead Sciences; GlaxoSmithKline/ViiV; Merck; Shionogi

Grant/Research SupportNIH; Gilead Sciences; ViiV

Editorial BoardsUpToDate; Clinical Infectious Diseases

Paul Sax, MD

Disclosures

Consultant/Advisory BoardGilead Sciences; GlaxoSmithKline/ViiV; Merck; Shionogi

Grant/Research SupportNIH; Gilead Sciences; ViiV

Editorial BoardsUpToDate; Clinical Infectious Diseases

ACIP Recommends Pneumococcal Conjugate Vaccine for HIV-Infected Adults

Topics

Authors